Talecris Biotherapeutics Rises 11% in IPO

October 02, 2009

Share:

Talecris Biotherapeutics offered 50 million shares at $19 per share in its IPO, raising a total of $950 million. The company's private equity backers, Cerberus Capital Management and Ampersand Ventures, sold about 15.8 million shares for $300 million, reducing their stake in Talecris from 97% to 56%. Cerberus is estimated to have earned 23 times its investment in the company. Talecris plans to use $514 million of its proceeds to pay down money owed under its first and second lien term loans.